# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `full27_study-forensics-032_Claude_Haiku_e2b152`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T18:03:48.232917+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **75.6/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, missed_key_insight, unsupported_intermediate_step
**Forensic flags:** 2
**Consistency findings:** 7
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 1.2/8 | 4.1/8 | 4.8/6 | 3.6/6 | 6.0/6 | 6.4/8 | 8.0/8 | 3.0/10 | 8.5/10 | **75.6/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** evidence_matches_claim, cautious_scope_control, none_or_minor, decorative_uncertainty, mechanism_not_demonstrated

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :white_check_mark: (1 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 1
- Unsupported: 0
- Contradicted: 0


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[STYLISTIC]** `unnamed_mechanism`: Describes mechanism without naming the concept — under-explicit
  - `steps[6]`: "CLASSIFICATION DECISION: This is overclaim, not merely mechanism_vs_evidence, because the company is"


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 1.2/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[6]`: "CLASSIFICATION DECISION: This is overclaim, not merely mechanism_vs_evidence, because the company is actively selling ca"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[3]`: "LDL cholesterol is a validated surrogate endpoint for cardiovascular outcomes in this population"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.6/6
  - (+) `uncertainties[1]`: "Whether LDL reduction is a well-validated surrogate for cardiovascular outcomes specifically in familial hypercholestero"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - (-) `uncertainties[2]`: "The exact wording of the company's regulatory submission vs. the press announcement (the summary conflates them)"
    _Listed but never addressed in reasoning_
  - Note: 4 uncertainties (4 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[1]`: "solid: If LDL reduction in this population were a fully validated surrogate endpoint with established clinical relevance"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 include rejection reasoning

**Self Monitoring Quality:** 6.4/8
  - (+) `self_check[3]`: "Is this overclaim or mechanism_vs_evidence? Overclaim, because the language is actively promotional ('major breakthrough"
    _Most substantive self-verification step_
  - Note: 6 self-check items
  - Note: Self-check quality: 0 deep, 6 arithmetic, 0 fluff

**Mechanism Quality:** 3.0/10
  - (+) `(mechanism analysis)`: "CLASSIFICATION DECISION: This is overclaim, not merely mechanism_vs_evidence, because the company is actively selling ca"
    _Mechanism description_
  - Note: Describes mechanism but does not name concept

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.69, 727 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "se 2 trial. this is biomarker/surrogate endpoint evidence, not clinical outcom"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "overclaim"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'The exact wording of the company's regulatory submission vs....' is listed but not addressed
  - `uncertainties[2]`: "The exact wording of the company's regulatory submission vs. the press announcement (the summary con"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/21 content words)
  - `key_claims[0]`: "The core overclaim: cardiovascular outcome benefit ('transform outcomes for patients at high risk of"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/13 content words)
  - `key_claims[1]`: "Promotional language ('major breakthrough,' 'cardiovascular protection') is used without qualificati"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (1/11 content words)
  - `key_claims[2]`: "The accelerated approval strategy amplifies the overclaim by treating a biomarker as sufficient evid"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/12 content words)
  - `key_claims[3]`: "The 4-year gap to outcome data is acknowledged but does not prevent the company from making outcome-"
- **[FAIL]** `[MEDIUM CONFIDENCE]` `assumption_reasoning`: Assumption 4 may be contradicted by step 2
  - `assumptions[3]`: "LDL cholesterol is a validated surrogate endpoint for cardiovascular outcomes in this population"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 3 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[2]`: "The exact wording of the company's regulatory submission vs. the press announcement (the summary con"
- **[NOTE]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Causal mechanism described but underlying concept not named
  - `final_answer`: "overclaim"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 14870ms

**Final Answer:** overclaim

**Confidence:** 0.92

**Assumptions:**
- The Phase 2 trial is a legitimate randomized controlled trial with appropriate controls
- The 65% LDL reduction is accurately measured and statistically significant
- The 12-week safety data for liver function is reliable
- LDL cholesterol is a validated surrogate endpoint for cardiovascular outcomes in this population
- The company's statements represent the primary claims being made to the public and regulators

**Reasoning Steps:**
1. EVIDENCE TIER IDENTIFICATION: The study measured biomarkers (LDL cholesterol, liver safety) over 12 weeks in a Phase 2 trial. This is biomarker/surrogate endpoint evidence, not clinical outcome evidence.
2. CONCLUSION TIER IDENTIFICATION: The company claims the drug will 'transform outcomes for patients at high risk of heart attack and stroke' — this is a human therapeutic claim about hard cardiovascular endpoints (MI, stroke), not surrogate endpoints.
3. BRIDGE GAP ANALYSIS: There is a critical gap between biomarker reduction and clinical cardiovascular outcomes. The text explicitly states 'no cardiovascular events were tracked' and outcomes data will not arrive for 4+ years.
4. RHETORICAL INFLATION CHECK: The language used is actively promotional: 'major breakthrough,' 'transform outcomes,' 'cardiovascular protection.' These are not hedged as hypothetical or preliminary; they are stated as established benefits.
5. SURROGATE ENDPOINT VALIDITY: While LDL reduction is associated with cardiovascular benefit in some populations, a 65% reduction in a 12-week Phase 2 trial does NOT establish that this specific drug will reduce heart attacks or strokes. The surrogate-to-outcome bridge is assumed, not proven.
6. ACCELERATED APPROVAL CONCERN: The company is pursuing accelerated approval based solely on biomarker data, which further inflates the claim beyond what the evidence supports. Accelerated approval for a surrogate endpoint is appropriate only if the surrogate is well-validated; the text provides no evidence of such validation for this drug.
7. CLASSIFICATION DECISION: This is overclaim, not merely mechanism_vs_evidence, because the company is actively selling cardiovascular benefit ('transform outcomes,' 'major breakthrough') based on a biomarker in a short-term Phase 2 trial. The rhetorical inflation is the primary forensic problem.

**Key Claims:**
- The core overclaim: cardiovascular outcome benefit ('transform outcomes for patients at high risk of heart attack and stroke') is claimed based on a 12-week biomarker study with no cardiovascular event tracking.
- Promotional language ('major breakthrough,' 'cardiovascular protection') is used without qualification, despite the absence of outcome data.
- The accelerated approval strategy amplifies the overclaim by treating a biomarker as sufficient evidence of clinical benefit.
- The 4-year gap to outcome data is acknowledged but does not prevent the company from making outcome-level claims in the present tense.

**Alternative Hypotheses:**
- mechanism_vs_evidence: If the text had been more cautious (e.g., 'LDL reduction may eventually translate to cardiovascular benefit, pending outcome trials'), the primary issue would be the evidence-tier gap rather than rhetorical inflation. But the actual language is promotional.
- solid: If LDL reduction in this population were a fully validated surrogate endpoint with established clinical relevance, and if the company had explicitly stated that cardiovascular benefit is hypothetical pending outcome data, the claims might be defensible. But neither condition is met in the text.

**Uncertainties:**
- Whether the Phase 2 trial had appropriate controls and randomization (assumed yes, but not stated in the summary)
- Whether LDL reduction is a well-validated surrogate for cardiovascular outcomes specifically in familial hypercholesterolaemia patients on maximum statin therapy (the text does not address this)
- The exact wording of the company's regulatory submission vs. the press announcement (the summary conflates them)
- Whether the accelerated approval pathway is being pursued under FDA guidance that accepts LDL reduction as a valid surrogate in this indication (context not provided)

**Self-Verification:**
- Did I correctly identify the evidence tier? Yes — biomarkers (LDL, liver safety) measured in a Phase 2 trial is tier 3 (biomarker/surrogate endpoint).
- Did I correctly identify the conclusion tier? Yes — 'transform outcomes,' 'cardiovascular protection,' 'high risk of heart attack and stroke' are tier 5 (clinical human outcomes), not tier 3.
- Is the bridge supported? No — the text explicitly states no cardiovascular events were tracked and outcomes data is 4+ years away.
- Is this overclaim or mechanism_vs_evidence? Overclaim, because the language is actively promotional ('major breakthrough,' 'transform outcomes') rather than cautious or hedged. The company is selling a clinical benefit, not hypothesizing one.
- Did I miss any solid aspects? No — the Phase 2 biomarker data itself may be solid, but the claims made from it are not.
- Did I overreach? No — the text itself provides the evidence of overclaim through its promotional language and the explicit acknowledgment that outcome data is pending.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 1.2/8 `#.........`
- Structural Reasoning: 4.1/8 `#####.....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.6/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 6.4/8 `########..`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 3.0/10 `###.......`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **75.6/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (1.2/8)
- Structural Reasoning: Claude Haiku (4.1/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.6/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (6.4/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (3.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 14.9s | 75.6/100 | 5.1 |

Failure modes observed: decorative_uncertainty, missed_key_insight, unsupported_intermediate_step.
